Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{017529c9985d4fa3adcc3df661bdf5a5,
title = "A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments",
abstract = "OBJECTIVES: The objective of this work was to develop a tool for decision support, providing simultaneous predictions of the risk of loco-regional failure (LRF) and distant metastasis (DM) after definitive treatment for head-and-neck squamous cell carcinoma (HNSCC).MATERIALS AND METHODS: Retrospective data for 560HNSCC patients were used to generate a multi-endpoint model, combining three cause-specific Cox models (LRF, DM and death with no evidence of disease (death NED)). The model was used to generate risk profiles of patients eligible for/included in a de-intensification study (RTOG 1016) and a dose escalation study (CONTRAST), respectively, to illustrate model predictions versus classic inclusion/exclusion criteria for clinical trials. The model is published as an on-line interactive tool (https://katrin.shinyapps.io/HNSCCmodel/).RESULTS: The final model included pre-selected clinical variables (tumor subsite, T stage, N stage, smoking status, age and performance status) and one additional variable (tumor volume). The treatment failure discrimination ability of the developed model was superior of that of UICC staging, 8(th) edition (AUCLRF=72.7{\%} vs 64.2{\%}, p<0.001 and AUCDM=70.7{\%} vs 58.8{\%}, p<0.001). Using the model for trial inclusion simulation, it was found that 14{\%} of patients eligible for the de-intensification study had>20{\%} risk of tumor relapse. Conversely, 9 of the 15 dose escalation trial participants had LRF risks<20{\%}.CONCLUSION: A multi-endpoint model was generated and published as an on-line interactive tool. Its potential in decision support was illustrated by generating risk profiles for patients eligible for/included in clinical trials for HNSCC.",
keywords = "Journal Article",
author = "Katrin H{\aa}kansson and Rasmussen, {Jacob H} and Rasmussen, {Gregers B} and Jeppe Friborg and Gerds, {Thomas A} and Fischer, {Barbara Malene} and Andersen, {Flemming L} and Bentzen, {S{\o}ren M} and Lena Specht and Vogelius, {Ivan R}",
note = "Copyright {\circledC} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "11",
doi = "10.1016/j.oraloncology.2017.09.018",
language = "English",
volume = "74",
pages = "77--82",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments

AU - Håkansson, Katrin

AU - Rasmussen, Jacob H

AU - Rasmussen, Gregers B

AU - Friborg, Jeppe

AU - Gerds, Thomas A

AU - Fischer, Barbara Malene

AU - Andersen, Flemming L

AU - Bentzen, Søren M

AU - Specht, Lena

AU - Vogelius, Ivan R

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/11

Y1 - 2017/11

N2 - OBJECTIVES: The objective of this work was to develop a tool for decision support, providing simultaneous predictions of the risk of loco-regional failure (LRF) and distant metastasis (DM) after definitive treatment for head-and-neck squamous cell carcinoma (HNSCC).MATERIALS AND METHODS: Retrospective data for 560HNSCC patients were used to generate a multi-endpoint model, combining three cause-specific Cox models (LRF, DM and death with no evidence of disease (death NED)). The model was used to generate risk profiles of patients eligible for/included in a de-intensification study (RTOG 1016) and a dose escalation study (CONTRAST), respectively, to illustrate model predictions versus classic inclusion/exclusion criteria for clinical trials. The model is published as an on-line interactive tool (https://katrin.shinyapps.io/HNSCCmodel/).RESULTS: The final model included pre-selected clinical variables (tumor subsite, T stage, N stage, smoking status, age and performance status) and one additional variable (tumor volume). The treatment failure discrimination ability of the developed model was superior of that of UICC staging, 8(th) edition (AUCLRF=72.7% vs 64.2%, p<0.001 and AUCDM=70.7% vs 58.8%, p<0.001). Using the model for trial inclusion simulation, it was found that 14% of patients eligible for the de-intensification study had>20% risk of tumor relapse. Conversely, 9 of the 15 dose escalation trial participants had LRF risks<20%.CONCLUSION: A multi-endpoint model was generated and published as an on-line interactive tool. Its potential in decision support was illustrated by generating risk profiles for patients eligible for/included in clinical trials for HNSCC.

AB - OBJECTIVES: The objective of this work was to develop a tool for decision support, providing simultaneous predictions of the risk of loco-regional failure (LRF) and distant metastasis (DM) after definitive treatment for head-and-neck squamous cell carcinoma (HNSCC).MATERIALS AND METHODS: Retrospective data for 560HNSCC patients were used to generate a multi-endpoint model, combining three cause-specific Cox models (LRF, DM and death with no evidence of disease (death NED)). The model was used to generate risk profiles of patients eligible for/included in a de-intensification study (RTOG 1016) and a dose escalation study (CONTRAST), respectively, to illustrate model predictions versus classic inclusion/exclusion criteria for clinical trials. The model is published as an on-line interactive tool (https://katrin.shinyapps.io/HNSCCmodel/).RESULTS: The final model included pre-selected clinical variables (tumor subsite, T stage, N stage, smoking status, age and performance status) and one additional variable (tumor volume). The treatment failure discrimination ability of the developed model was superior of that of UICC staging, 8(th) edition (AUCLRF=72.7% vs 64.2%, p<0.001 and AUCDM=70.7% vs 58.8%, p<0.001). Using the model for trial inclusion simulation, it was found that 14% of patients eligible for the de-intensification study had>20% risk of tumor relapse. Conversely, 9 of the 15 dose escalation trial participants had LRF risks<20%.CONCLUSION: A multi-endpoint model was generated and published as an on-line interactive tool. Its potential in decision support was illustrated by generating risk profiles for patients eligible for/included in clinical trials for HNSCC.

KW - Journal Article

U2 - 10.1016/j.oraloncology.2017.09.018

DO - 10.1016/j.oraloncology.2017.09.018

M3 - Journal article

VL - 74

SP - 77

EP - 82

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -

ID: 52024805